Published in:
Open Access
01-12-2018 | Letter
The pharmacokinetic challenge of treating invasive aspergillosis complicating severe influenzae assisted by extracorporeal membrane oxygenation
Authors:
Hadrien Winiszewski, Anne-Claire Rougny, Jennifer Lagoutte-Renosi, Laurence Millon, Gilles Capellier, Jean-Christophe Navellou, Gael Piton, Anne-Laure Clairet
Published in:
Critical Care
|
Issue 1/2018
Login to get access
Excerpt
Invasive aspergillosis (IA) complicates 19% of patients requiring ICU admission for severe influenza [
1]. Despite recent development of isavuconazole, voriconazole remains the first therapeutic option for IA among patients without hematological malignancy [
2]. However, among patients requiring the use of extracorporeal membrane oxygenation (ECMO) as rescue therapy for extremely severe acute respiratory failure [
1], the use of ECMO per se has been reported as a cause of sequestration of voriconazole on the membrane. This phenomenon could induce low plasma concentrations of voriconazole and, therefore, limited efficacy [
3]. …